Skip to main content
SpringerLink
Log in

Metastasiertes Mammakarzinom

Differenzierte, möglichst zielgerichtete medikamentöse Therapie

Metastatic breast cancer

Differentiated and preferably targeted systemic treatment

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Das Mammakarzinom ist der häufigste Tumor bei Frauen, und 15–25% der Patientinnen entwickeln im Verlauf eine Metastasierung. Die medikamentöse Therapie des metastasierten Mammakarzinoms unterliegt gegenwärtig einem stetigen Wandel. So ergänzen zielgerichtete Therapien mittlerweile die klassische antihormonelle und zytostatische Therapie. Zielgerichtete Therapien attackieren Signaltransduktionswege von Tumorzellen durch Blockade von zellulären Rezeptoren, Kinasen oder Rezeptorliganden.

Schlussfolgerung

Der Beitrag soll einen Überblick über die neuesten, insbesondere über klinisch relevante Veränderungen der zielgerichteten medikamentösen Therapie des metastasierten Mammakarzinoms geben.

Abstract

Context

Breast cancer is the most frequent malignant tumor in women and 15–25% of all patients will eventually develop metastatic disease. The systemic treatment of metastatic breast cancer consists of cytotoxic, antiestrogenic and targeted agents. Knowledge of different signal transduction pathways underlying tumor cell growth and proliferation has led to the development of so-called biologicals that interfere with pathways at different levels. Different receptors, key proteins of intracellular pathways, tyrosine kinases or cytokines serve as tumor targets.

Conclusion

This article reviews the latest and especially the clinically relevant changes in the role of targeted therapy in the systemic treatment of metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Bachelot T, Bourgier C, Cropet C et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724

    Article  PubMed  CAS  Google Scholar 

  2. Bachelot T, Romieu G, Campone M et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71

    Article  PubMed  CAS  Google Scholar 

  3. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

    Article  PubMed  CAS  Google Scholar 

  4. Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

    Article  PubMed  CAS  Google Scholar 

  5. Bergh J, Jonsson PE, Lidbrink EK et al (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919–1925

    Article  PubMed  CAS  Google Scholar 

  6. Blackwell KL, Miles D, Gianni L et al (2012) Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and Lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane, ASCO Annual Meeting Proceedings, LBA1. J Clin Oncol 30 (suppl 18)

  7. Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258

    Article  PubMed  CAS  Google Scholar 

  8. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286–4293

    Article  PubMed  CAS  Google Scholar 

  9. Burris HA 3rd, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405

    Article  PubMed  CAS  Google Scholar 

  10. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796

    Article  PubMed  Google Scholar 

  11. Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543

    Article  PubMed  CAS  Google Scholar 

  12. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70

    Article  Google Scholar 

  13. Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670

    Article  PubMed  CAS  Google Scholar 

  14. Chia SK, Speers CH, D’yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979

    Article  PubMed  Google Scholar 

  15. Cortes J, O’shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923

    Article  PubMed  CAS  Google Scholar 

  16. Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594–4600

    Article  Google Scholar 

  17. Gelmon KA, Boyle F, Kaufman B et al (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919, ASCO Annual Meeting Proceedings, LBA671. J Clin Oncol 30(Suppl 18)

  18. Gianni L, Romieu G, Lichinitser M et al (2011) First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC), 34th Annual SABCS, Abstract S4–8. Cancer Res 71, 24 (Suppl 3)

  19. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52

    Article  PubMed  Google Scholar 

  20. Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 6:136–141

    Google Scholar 

  21. Howell A, Pippen J, Elledge RM et al (2005) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104:236–239

    Article  PubMed  CAS  Google Scholar 

  22. Jatoi I, Chen BE, Anderson WF et al (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690

    Article  PubMed  Google Scholar 

  23. Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

    Article  PubMed  CAS  Google Scholar 

  24. Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537

    Article  PubMed  CAS  Google Scholar 

  25. Kaufman PA, Awada A, Twelves C et al (2012) A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes, 35th Annual SABCS, Abstract S6-6. Cancer Res 72, 24 (Suppl 3)

  26. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277

    Article  PubMed  Google Scholar 

  27. Kris MG, Benowitz SI, Adams S et al (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 28:5327–5347

    Article  PubMed  Google Scholar 

  28. Krop IE, Lorusso P, Miller KD et al (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234–3241

    Article  PubMed  CAS  Google Scholar 

  29. Lang I, Brodowicz T, Ryvo L et al (2013) Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14:125–133

    Article  PubMed  CAS  Google Scholar 

  30. Levi F, Lucchini F, Negri E et al (2004) Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101:2843–2850

    Article  PubMed  Google Scholar 

  31. Lopez-Knowles E, O’toole SA, Mcneil CM et al (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126:1121–1131

    PubMed  CAS  Google Scholar 

  32. Malvezzi M, Bertuccio P, Levi F et al (2012) European cancer mortality predictions for the year 2012. Ann Oncol 23:1044–1052

    Article  PubMed  CAS  Google Scholar 

  33. Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435–444

    Article  PubMed  CAS  Google Scholar 

  34. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3247

    Article  PubMed  CAS  Google Scholar 

  35. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  PubMed  CAS  Google Scholar 

  36. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  37. Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109

    Article  PubMed  CAS  Google Scholar 

  38. Papaldo P, Fabi A, Ferretti G et al (2006) A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 17:630–636

    Article  PubMed  CAS  Google Scholar 

  39. Perez Ea DL, Kocsis J, et al (2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized multicenter open-label phase 2 study (TDM 4450G). Ann Oncol 21

  40. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) (2012) Krebs in Deutschland 2007/2008. 8. Ausgabe. Berlin, S 64–67

  41. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

    Article  PubMed  CAS  Google Scholar 

  42. Robertson JF, Lindemann JP, Llombart-Cussac A et al (2012) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‚FIRST‘ study. Breast Cancer Res Treat 136:503–511

    Article  PubMed  CAS  Google Scholar 

  43. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  44. Smith BD, Jiang J, Mclaughlin SS et al (2011) Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 29:4647–4653

    Article  PubMed  Google Scholar 

  45. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874

    Article  PubMed  CAS  Google Scholar 

  46. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791

    Article  PubMed  CAS  Google Scholar 

  47. Villarreal-Garza C, Cortes J, Andre F et al (2012) mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 23:2526–2535

    Article  PubMed  CAS  Google Scholar 

  48. Von Minckwitz G, Du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006

    Article  Google Scholar 

  49. Wicha MS (2009) Targeting breast cancer stem cells. Breast 18 (Suppl 3):S56–S58

    Article  PubMed  Google Scholar 

  50. Wolff AC, Lazar AA, Bondarenko I et al (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195–202

    Article  PubMed  CAS  Google Scholar 

  51. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Deutschland

    J. Eucker, P. Habbel & K. Possinger

Authors
  1. J. Eucker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Habbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Possinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Eucker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eucker, J., Habbel, P. & Possinger, K. Metastasiertes Mammakarzinom. Onkologe 19, 487–493 (2013). https://doi.org/10.1007/s00761-013-2450-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-013-2450-z

Schlüsselwörter

Keywords

Search

Navigation